Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Equities research analysts at Zacks Research lowered their FY2023 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Tuesday, January 23rd. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.85) for […]